痰热清注射液治疗心力衰竭伴肺部感染患者的临床效果及对T细胞亚群的影响

Clinical effect of Tanreqing injection in the treatment of heart failure patients with pulmonary infection and its influence on T cell subsets

目的探讨痰热清注射液治疗心力衰竭伴肺部感染患者的临床效果及对T细胞亚群的影响。方法选择我院收治的112例心力衰竭伴肺部感染患者作为研究对象,根据随机抽样法将其分为对照组和研究组,每组56例。对照组患者接受头孢哌酮/舒巴坦治疗,研究组患者在对照组的基础上联合痰热清注射液治疗,比较两组患者的治疗效果。结果研究组的治疗总有效率高于对照组(P<0.05);治疗后,两组患者IL-6、BNP、CRP、TNF-α与PCT水平均显著降低,且研究组低于对照组(P<0.05);治疗后,两组患者CD3+、CD4+、CD4+/CD8+均显著升高,CD8+显著降低,且研究组优于对照组(P<0.05)。结论痰热清注射液有助于提高机体免疫功能,抑制炎性反应,疗效确切,对促进心力衰竭伴肺部感染患者病情康复具有积极意义。

Objective To investigate the clinical effect of Tanreqing injection in the treatment of heart failure patients with pulmonary infection and its influence on T cell subsets.Methods A total of 112 cases of heart failure with pulmonary infection admitted in our hospital were selected as the research objects.According to the random sampling method,the patients were divided into control group and study group,with 56 cases in each group.The control group was treated with cefoperazone/sulbactam,and the study group was treated with Tanreqing injection on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment of the study group was higher than that of the control group(P<0.05);after treatment,the levels of IL-6,BNP,CRP,TNF-αand PCT in the two groups significantly decreased,and those in the study group were lower than the control group(P<0.05);after treatment,CD3+,CD4+and CD4+/CD8+significantly increased,CD8+significantly decreased in both groups,and those in the study group were superior to the control group(P<0.05).Conclusion Tanreqing injection can improve the immune function of the body,inhibit the inflammatory response,and has definite curative effect.It is of positive significance to promote the rehabilitation of patients with heart failure and pulmonary infection.